The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
Open accessAbstract
Following the discovery of the first effective antiviral compound (idoxuridine) in 1959, nucleoside analogues, especially acyclovir (ACV) for the treatment of herpesvirus infections, have dominated antiviral therapy for several decades. However, ACV and similar acyclic nucleosides suffer from low aqueous solubility and low bioavailability following oral administration. Derivatives of acyclic nucleosides, typically esters, were developed to overcome this problem and valaciclovir, the valine ester of ACV, was among the first of a new series of compounds that were readily metabolized upon oral administration to produce the antiviral nucleoside in vivo, thus increasing the bioavailility by several fold. Concurrently, famciclovir was developed as an oral formulation of penciclovir. These antiviral ‘prodrugs’ thus established a principle that has led to many successful drugs including both nucleoside and nucleotide analogues for the control of several virus infections, notably those caused by herpes‐, retro‐ and hepatitisviruses. This review will chart the origins and development of the most important of the antiviral prodrugs to date. British Journal of Pharmacology(2006)147, 1–11. doi:10.1038/sj.bjp.0706446
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
Elion, G. B., Furman, P. A., Fyfe, J. A., Miranda, P. D., Beauchamp, L., & Schaeffer, H. J. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5716 · Cited by 1,591
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341 · cited 1×
“…such antiretroviral regimen is based on the combination of TDF with lamivudine and efavirenz: this drug combination regimen is as efficacious as the combination of stavudine with lamivudine and efavirenz, but is associated with a better lipid profile and less lipodystrophy (Gallant et al., 2004).”
BackgroundAdefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group
Schaeffer, H. J., Beauchamp, L., de Miranda, P., Elion, G. B., Bauer, D. J., & Collins, P. (1978) · Nature · doi:10.1038/272583a0 · Cited by 1,140
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Antiviral drugs in current clinical use
De Clercq, E. (2004) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.02.009 · Cited by 947
Self-citationA novel selective broad-spectrum anti-DNA virus agent
Clercq, E. D., Holý, A., Rosenberg, I., Sakuma, T., Balzarini, J., & Maudgal, P. C. (1986) · Nature · doi:10.1038/323464a0 · Cited by 764
Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M., Paavonen, J., Morrow, R. A., Beutner, K. R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035144 · Cited by 720
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Self-citationTransient Receptor Potential Cation Channels in Disease
Nilius, B., Owsianik, G., Voets, T., & Peters, J. A. (2007) · Physiological Reviews · doi:10.1152/physrev.00021.2006 · Cited by 1,399
Prescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
Tariq, S., Wani, S., Rasool, W., Shafi, K., Bhat, M. A., Prabhakar, A., Shalla, A. H., & Rather, M. A. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103580 · Cited by 693
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Cellular Uptake of Nanoparticles versus Small Molecules: A Matter of Size
Mosquera, J., García, I., & Liz-Marzán, L. M. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00292 · Cited by 487
Antiviral drugs for cytomegalovirus diseases
Biron, K. K. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.05.002 · Cited by 468
First oncolytic virus approved for melanoma immunotherapy
Pol, J., Kroemer, G., & Galluzzi, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1115641 · Cited by 392
Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, G., Madou, M. J., Kalra, S., Chopra, V., Ghosh, D., & Martinez-Chapa, S. O. (2020) · ACS Nano · doi:10.1021/acsnano.0c04006 · Cited by 385
Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry
De Silva, D. D., Rapior, S., Sudarman, E., Stadler, M., Xu, J., Aisyah Alias, S., & Hyde, K. D. (2013) · Fungal Diversity · doi:10.1007/s13225-013-0265-2 · Cited by 271
Wigal, S. B., Wong, A. A., Jun, A., Stehli, A., Steinberg-Epstein, R., & Lerner, M. A. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0095 · Cited by 26
Metadata
- Authors
- De Clercq, E., & Field, H. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 147
- Issue
- 1
- Pages
- 1-11
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2033899181
- Cited by
- 336
- References
- 39
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.